Study Evaluating the Efficacy and Safety of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi Directional Device in Subjects With Bilateral Nasal Polyposis Followed by an 8-Week Open-Label Extension Phase to Assess Safety

Montefiore Medical Center, The Bronx

EVMS Depart. Of Otolaryngology, Norfolk

National Allergy, Asthma & Urticaria Centers of Charleston, P.A., North Charleston

University of South Florida Asthma, Allergy & Immunology, Tampa

Optimed Research, Columbus

Ear Nose and Throat Associates of Texas, Frisco

Cleveland Clinic, Cleveland

Allergy, Asthma & Sinus Center, S.C., Greenfield

Clinical Research Group of Montana, PLLC, Bozeman

NU Feinberg School of Medicine Depart. of Otolaryngology-Head & Neck Surgery, Chicago

Chicago ENT, Chicago

The Center for Pharmaceutical Research, P.C., Kansas City

Allergy, Asthma & Clinical Research Center, Oklahoma City

Vital Prospects Clinical Research Institute, Tulsa

ENTTEX, Plano

AARA Research Center, Dallas

Colorado Allergy and Asthma Centers, P.C., Denver

Asthma & Allergy Associates, P.C., Colorado Springs

Colorado ENT & Allergy, Colorado Springs

SC Clinical Research, Inc., Tucson

California Allergy & Asthma Medical Group, Inc., Los Angeles

Peninsula Research Associates, Inc., Rolling Hills Estates

California Medical Clinic for Headache, Santa Monica

Allergy & Asthma Specialists Medical Group, Huntington Beach

Choc PSF, AMC, Division of AA & I, Orange

Kern Allergy and Medical Research, Inc., Bakersfield

California Allergy and Asthma Palmdale, Palmdale

Central California Clinical Research, Fresno

Northeast Medical Research Associates, Inc, North Dartmouth

Coastal Ear, Nose and Throat, LLC, Neptune City

Ottawa Allergy Research Corporation, Ottawa

CHUM Hôtel-Dieu, Montreal

Dr. Jaime Del Carpio, Montreal